Eledon Pharmaceuticals, Inc.
ELDNNasdaq
$4.07
↑ +6.0%Jul 17 close · end-of-day
Price
1Y↑ +7.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$457.6M
Enterprise Value
$346.5M
P/E
—
P/S
—
P/B
10.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$78.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-174.6%
ROIC
—
Debt / Equity
—
Net Cash
$111.1M
Return 1Y
+8.5%
Company profile
Eledon Pharmaceuticals, Inc. focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS.
- CEO
- David-Alexandre C. Gros
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- https://eledon.com/
Earnings
ELDN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.33↑ +312.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.5M | -$36.9M | -$88.4M | -$43.0M | — | — |
| Net income | -$22.8M | -$34.5M | -$88.0M | -$116.5M | -$36.2M | -$45.6M |
| Diluted EPS | — | -$2.33 | -$6.16 | -$4.73 | -$0.66 | -$0.52 |
| Operating cash flow | -$15.2M | -$28.9M | -$28.4M | -$39.5M | -$47.3M | -$62.3M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.5M | -$20.5M | — | -$18.0M | -$24.7M | -$19.1M | — | -$21.2M |
| Net income | -$44.9M | $77.0M | -$44.6M | -$6.5M | -$11.2M | -$17.5M | -$10.4M | -$39.0M |
| Diluted EPS | -$0.92 | -$0.28 | $1.19 | -$0.08 | -$0.13 | -$0.21 | -$0.10 | -$0.33 |
| Operating cash flow | -$7.8M | -$11.8M | -$19.0M | -$16.1M | -$17.7M | -$14.5M | -$14.1M | -$22.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-10 | McBride John S. | Option exercise | 3,430 | $0.00 | $0.00 | filing |
| 2026-01-10 | Hillson Jan | Option exercise | 3,430 | $0.00 | $0.00 | filing |
| 2026-01-10 | Kirk Allan | Option exercise | 3,430 | $0.00 | $0.00 | filing |
| 2026-01-10 | Katkin Keith | Option exercise | 8,575 | $0.00 | $0.00 | filing |
| 2026-01-10 | Lee June | Option exercise | 3,430 | $0.00 | $0.00 | filing |
| 2026-01-10 | Robinson James A. Jr. | Option exercise | 3,430 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.